Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Strata Critical Medical (SRTAW) Interest & Investment Income (2019 - 2025)

Historic Interest & Investment Income for Strata Critical Medical (SRTAW) over the last 6 years, with Q3 2025 value amounting to $1.1 million.

  • Strata Critical Medical's Interest & Investment Income fell 3611.11% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.2 million, marking a year-over-year decrease of 3416.58%. This contributed to the annual value of $7.2 million for FY2024, which is 1454.63% down from last year.
  • As of Q3 2025, Strata Critical Medical's Interest & Investment Income stood at $1.1 million, which was down 3611.11% from $1.2 million recorded in Q2 2025.
  • Strata Critical Medical's Interest & Investment Income's 5-year high stood at $2.3 million during Q4 2023, with a 5-year trough of $4136.0 in Q1 2021.
  • Moreover, its 4-year median value for Interest & Investment Income was $1.8 million (2024), whereas its average is $1.6 million.
  • As far as peak fluctuations go, Strata Critical Medical's Interest & Investment Income plummeted by 9952.42% in 2021, and later crashed by 1391.43% in 2024.
  • Quarter analysis of 4 years shows Strata Critical Medical's Interest & Investment Income stood at $4136.0 in 2021, then surged by 54638.88% to $2.3 million in 2023, then fell by 29.77% to $1.6 million in 2024, then decreased by 29.12% to $1.1 million in 2025.
  • Its Interest & Investment Income stands at $1.1 million for Q3 2025, versus $1.2 million for Q2 2025 and $1.3 million for Q1 2025.